Immune Related Adverse Events Following Checkpoint Inhibitors
Posted Date: Oct 14, 2019
- Investigator: Eric Vick
- Specialties: Cancer, Head and Neck Cancer, Lymphoma, Oncology
- Type of Study: Observational/Survey
Immunotherapy is one of the most promising new treatment options available in oncology. In stimulating the immune system to more effectively recognize cancer, immunotherapy has rendered cancer more susceptible to multiple treatment modalities. Immunotherapy has already changed the landscape of how certain tumors are treated and has been approved by the FDA for the first ever, for a tissue origin-independent indication: microsatellite instability (MSI) high tumors. These breakthroughs are not without drawbacks. Immunotherapy typically has a very favorable side effect profile, with typical adverse events including infusion site reactions and rare anaphylaxis. More unique to immune therapy is the spectrum of immune-related adverse events (IRAEs). These include thyroiditis, colitis, pneumonitis, dermatitis, adrenalitis, and others which are driven by the unmasking nature of immunotherapy causing off-target effects and leading to an autoimmune disease of as of yet undetermined significance. The primary objective of this protocol is to examine the treatment of immune-related adverse events for patients receiving immune checkpoint inhibitor (ICI) therapy when they arrive at the hospital.
Checkpoint Inhibitors, Immune Related Adverse Events, Cancer
For More Information: